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Abstract  
Objectives To assess the association between the use of medications with anti-
cholinergic activity and the subsequent risk of injurious falls in older aged adults.  
Design Prospective, population-based study, using data from The Irish Longitudinal 
study on Ageing. 
Setting Irish population  
Participants 2,696 community-dwelling dementia-free men and women aged 65 years 
and older.  
Measurements Self-reported injurious falls reported once, approximately two-years 
after baseline interview. Self-reported regular medication use at baseline interview. 
Pharmacy dispensing records from the Irish Health Service Executive Primary Care 
Reimbursement Service in a subset (n=1,553). 
Results Injurious falls were reported by 9% and 17% of men and women. In men, the 
use of medications with definite anti-cholinergic activity was associated with an 
increased risk of subsequent injurious falls (adjusted relative risk [aRR] 2.55, 95% CI 
1.33 to 4.88), but the risk of having any fall and the number of falls reported were not 
significantly increased. Increased anti-cholinergic burden was associated with greater 
injurious falls risk. However, no associations were observed for women. Findings were 
similar using pharmacy dispensing records. The aRR for medications with definite anti-
cholinergic activity dispensed in the month prior to baseline and subsequent injurious 
falls in men was 2.53 (95% CI 1.15 to 5.54).  
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Conclusion The regular use of medications with anti-cholinergic activity is associated 
with subsequent injurious falls in older men. However, falls were self-reported after a 
two-year recall so were potentially under-reported.  Further research is required to 
validate this finding in men, and to consider the effect of duration and dose of anti-
cholinergic medications.  
Key words: anti-cholinergic; anti-muscarinic; falls; injury; elderly 
5 
 
5 
 
INTRODUCTION 
Fall-related injuries are a major public health concern 1. Around 30% of community-
dwelling persons aged over 65 years fall annually 2,3. More than half of falls result in 
injury ranging from fractures and head injury to bruises, cuts, and abrasions 3,4. 
Injurious falls can cause lengthy hospitalisation and institutionalisation 5. Less serious 
injuries can still cause disability and fear of falling, decreased activity and poorer quality 
of life 2,4–6. 
Falls risk involves a complex interplay between intrinsic and extrinsic factors.  
Depression, comorbidity, urinary incontinence, pain, impaired vision, and cognitive 
impairment are all linked to an increased risk of falls 7,8.  Some medications confer an 
increased falls risk, particularly antipsychotics, antidepressants and benzodiazepines 9. 
Possible explanations include sedative, autonomic and extrapyramidal effects, and the 
effects on alpha-adrenergic receptors of psychotropics 10–13. Anti-cholinergic 
medications block muscarinic cholinergic receptors and inhibit the parasympathetic 
nervous system 14. Common anti-cholinergic side-effects that may increase falls risk 
include blurred vision, tachycardia, sedation and confusion 15,16. The use of medicines 
with anti-cholinergic activity is common in older adults17, who are more susceptible to 
their effects, given age-related deficits in drug metabolism, elimination, and in 
cholinergic neurotransmission 17,18. These medications are prescribed for a variety of 
conditions including incontinence (e.g. Oxybutin), depression (e.g. Amitriptyline) and 
psychosis (e.g. Olanzapine) 15,16,18.  Older people are often prescribed a “cocktail” of 
medicines with anti-cholinergic activity resulting in accumulative burden increasing the 
risk of side-effects17.    
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Anti-cholinergic medications have been implicated with cognitive and functional 
decline in older populations, but there is limited evidence of an increased falls risk 11,19–
24.  We assessed the association between the use of medications with anti-cholinergic 
activity and subsequent falls and injurious falls over two years in community-dwelling 
dementia-free adults aged 65 years and older in Ireland. Fall injuries and risk factors for 
falls vary significantly by gender 5,25, hence we report results for men and women 
separately.  
 
METHODS 
 
Participants 
The Irish Longitudinal study on Ageing (TILDA) is a prospective study 
representative of the community-dwelling population aged 50 years and over in Ireland.  
At baseline (September 2009 - February 2011) each participant underwent an extensive 
in home face-to-face interview (N=8175), and was invited to complete a self-reported 
questionnaire (SCQ) and a nurse conducted health assessment.  Home interviews were 
conducted by professional interviewers (from Ipsos MORI) who completed additional 3-
day TILDA specific training. Households were initially selected from a clustered sample 
of Irish residential addresses with an overall response rate of 62.0%. The sample is 
described in detail elsewhere 26,27. TILDA was approved by the Faculty of Health 
Sciences Research Ethics Committee of Trinity College Dublin. Potential participants, 
who were unable to give consent due to dementia or cognitive impairment were 
excluded. 
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We studied participants aged 65 years and older and to improve data accuracy 
excluded those with dementia, institutionalized, or where falls data was provided by a 
proxy, leaving 2,696 participants for analysis (figure 1). 
 
Falls outcomes 
In TILDA’s second wave (April - December 2012), aimed to be undertaken 2-years 
post baseline, participants were asked “Have you fallen since your last interview?”, 
“How many times have you fallen since your last interview?”, and “Did you injure 
yourself seriously enough to need medical treatment?” (henceforth ‘injurious fall’).  
 
Baseline medications – self report 
Medication use was assessed both during home interview and by linkage to 
pharmacy records in a subset. Trained interviewers asked participants “Now I would 
like to record all medications that you take on a regular basis, like every day or every 
week. This will include prescription and non-prescription medications, over-the-
counter medicines, vitamins, and herbal and alternative medicines”, and viewed 
medication packages to enter the correct medication names and to reduce recall issues. 
Medications were assigned World Health Organisation (WHO) Anatomic Therapeutic 
Chemical (ATC) Classification codes28.  
 
Baseline medications – pharmacy dispensing records 
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Linkage to pharmacy dispensing records was available for those enrolled in the 
General Medical Services (GMS) Scheme, who consented, and for whom linkage was 
successful; details are described elsewhere 29. The GMS scheme entitles members to 
free health care and prescription medications at minimal cost. The Irish Health Service 
Executive Primary Care Reimbursement Service (HSE–PCRS) pharmacy claims database 
collates information on dispensed prescribed medications for individuals in the GMS 
scheme. Medications are coded using the WHO ATC 28. Dispensing records were 
extracted for the 30 days prior to the baseline interview. 
 
Anti-cholinergic assessment 
The anti-cholinergic burden of self-reported and recently dispensed medications 
was assessed using the Anti-cholinergic Cognitive Burden scale (ACB) 
www.agingbraincare.org/tools/abc-anticholinergic-cognitive-burden-scale/ 18,30. This is 
a frequently updated scale that classifies, through expert consensus and literature 
review, the evidence for anti-cholinergic activity of medications.  Medications with 
serum anti-cholinergic activity or in vitro affinity to muscarinic receptors but with no 
known clinically relevant negative cognitive effects are scored 1 , while drugs with 
established and clinically relevant anti-cholinergic effects are scored 2 or 3 based on 
blood-brain penetration and any reported association with delirium. 
For each participant, total anti-cholinergic burden was defined as the sum of ACB 
scores for all medications taken. As an alternate measure, the anti-cholinergic activity of 
the most severely rated medication taken was categorised as none (score 0), possibly 
(1) or definitely (2-3) anti-cholinergic.  
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We also coded the use of other medications reported to increase falls risk, but that 
lacked anti-cholinergic activity, as the number of antihypertensives (ATC C02, C07A, 
C08, C09A, or C09C), diuretics (C03), antipsychotics (N05A), sedatives and hypnotics 
(N05BA or N05C), and antidepressants (N06A) 9. 
 
Baseline covariates 
Covariates included were chosen because they are either known risk factors for falls 
7 or indications for the anti-cholinergic medications. Socio-demographic factors 
included gender, age, residential status (living alone), socioeconomic status (household 
income, education and employment status), and health behaviours of smoking status 
and alcoholism (Cut-annoyed-guilty-eye [CAGE] questionnaire score of ≥2, completed 
within the SCQ) 31. 
Physician diagnosis of the following health conditions was self-reported: 
hypertension, angina, heart attack, heart failure, diabetes, transient ischaemic attack 
(TIA), high cholesterol, heart murmur, arrhythmia, stroke, other cardiovascular disease, 
cataracts, glaucoma, age related macular degeneration (ARMD), chronic lung disease, 
asthma, osteoporosis, cancer, arthritis, stomach ulcer, liver disease, varicose ulcer, 
alcohol or substance abuse, Parkinson's disease, anxiety, depression, or other 
psychological disorder (emotional problem, mood swings, hallucinations, 
schizophrenia, or other).  
 Participants self-reported pain (none, mild, moderate or severe), urinary 
incontinence in the past 12 months, sleep problems, their vision and hearing quality 
(both excellent, very good, good, fair, or poor), and hospital admissions in the last year. 
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Disability was reported as any limitations in Instrumental Activities of Daily Living 
(IADL) or Activities of Daily Living (ADLs). Falls related history included falls in the last 
year, fractures (hip or wrist) or blackouts or fainting. Depressive symptoms were 
assessed using the Centre for Epidemiologic Studies Depression Scale 32. Cognition was 
assessed using the animal naming test, where participants were asked to name as many 
different animals as possible in one minute. 
 
Health assessment measures 
Health assessments were performed in one of two dedicated university centres. 
Functional mobility was measured via Timed Up-and-Go (TUG) which measures time to 
rise from a chair, walk 3m, and return to sitting 33 and gait speed at usual walking pace 
(cm/s).  Handgrip strength was measured using a dynamometer. Height and weight 
were measured using standard procedures for body mass index (BMI). The bone mass 
of a participant’s non-dominant foot was measured using quantitative heel ultrasound 
to provide an index of bone stiffness (SI). Osteoporosis was defined as SI ≤ 65%, 
osteopenia for SI 65%-86%, and normal bone density for SI >86% 34. Orthostatic blood 
pressure was measured using continuous beat-to-beat plethysmography (Finometer) 
during active stand. Orthostatic hypotension severity was graded by sustained failure to 
return to at least 90% of baseline systolic blood pressure at 40 seconds post stand, and 
at 110 seconds post stand 35. Further health assessment details can be found elsewhere 
26. 
 
Statistical analysis 
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We used Poisson regression to estimate the relative risk (RR) for the association 
between baseline anti-cholinergic medication use,  subsequent falls and injurious falls 
36. We used negative binomial regression to calculate the incidence rate ratio (IRR) 
relating medication use and the number of falls. Associations are provided adjusted for 
socio-demographics, self-reported comorbidities, health and fall-related covariates 
listed above, public healthcare coverage, duration between interviews, and use of other 
falls risk medications. Non-medication independent risk factors for injurious falls are 
reported. All analyses were conducted separately in men and women.  Associations for 
the interaction between age group (65-69, 70-74 and 75+ years) and definite anti-
cholingeric use and injurious falls are also reported.  
Analyses were repeated for participants attending a health assessment and 
among this group were additionally adjusted for the objective health measures. 
Continuous health measures were categorised into quintiles to enable non-linear 
relationships with the fall outcomes to be taken into account. Covariates with missing 
data were coded with a ‘missing’ category. Analyses were repeated for participants with 
linked pharmacy records, with baseline anti-cholinergic exposure defined by the 
medications dispensed in the 30 days before the TILDA interview.   
We performed a sensitivity analysis using survey weights provided by TILDA to 
determine whether differential refusal at baseline or loss to follow-up affected the 
validity of our main findings 27. All analyses were performed using Stata Version 12 
(StataCorp. 2011).  
 
RESULTS 
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Falls data at follow-up was collected for 1,286 men and 1,410 women. The mean 
(SD) time between baseline and follow-up was 24.2 (2.8) months, range 15.9 - 36.2 
months. A total of 118 (4%) participants reported regularly using at least one 
medication with definite anti-cholinergic activity, while 1,001 (37%) regularly used 
only medications with possible anti-cholinergic activity. The most commonly reported 
classes of medication with definite anti-cholinergic activity were antidepressants 
(n=58), urologicals (n=80), and antipsychotics (n=20), with the three most commonly 
reported medications by both men and women being the urological tolterodine (n=39), 
and antidepressants amitriptyline (n=32) and paroxetine (n=17). See appendix table 1 
for a full list of medications with anti-cholinergic activity. Medications with possible 
anti-cholinergic activity were reported from a range of therapeutic classes, most 
commonly cardiovascular (n=1,257), nervous system (n=402), and antithrombotic 
agents (n=198). The most frequently reported medications with possible anti-
cholinergic activity were the cardiac medicines furosemide (n=230), 
hydrochlorothiazide (n=217), and atenolol (n=212). 
 
Falls 
There were 711 (26%) fallers by the second interview, reporting 1,474 falls (271 
per 1000 person-years), and 344 (13%) reporting an injurious fall. In participants aged 
75 and 85 years and older, 31% and 16%, and 31% and 21%, reported a fall and an 
injurious fall, respectively. All falls outcomes were more common in women. A previous 
fall was a risk factor for injurious falls in men and women. Also, no current employment, 
depression, and pain, independently increased injurious falls risk in men while previous 
fracture, older age, and diagnoses of liver disease, osteoporosis, lung disease, and heart 
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attack increased falls risk among women (baseline characteristics in table 1). Among 
objective health measures only grip strength was independently associated with 
injurious falls in women and gait speed in men (baseline characteristics in appendix 
table 2). 
 
Self-reported anti-cholinergic medication use and falls 
In men, the regular use of medications with definite anti-cholinergic activity was 
associated with subsequent injurious falls (adjusted relative risk [aRR] 2.55, 95% CI 
1.33 to 4.88), but not with fallers or number of falls after covariate adjustment (table 2). 
The use of medications with possible anti-cholinergic activity alone was not associated 
with any falling outcomes. There was no association between the use of medications 
with anti-cholinergic activity and any falls outcomes among women.  Associations were 
not affected by use of survey response and attrition weights (appendix table 3).  
Interactions between age and anti-cholinergic medication use with respect to injurious 
falls were not statistically significant (p=0.38 for men, p=0.14 for women), but there 
was suggestion of a reduced association for participants aged over 75 years (appendix 
table 4).  
For men, a dose-response relationship was observed between total ACB score 
and injurious falls, with men with an ACB score of ≥5 having an aRR of 4.95 (95% CI 
2.11 to 11.65) for an injurious fall compared to those not taking any medications with 
anti-cholinergic activity (table 3).   
Among the  761 (59%) men attending the health assessment, significant 
associations were not attenuated when also adjusted for baseline objective health 
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measures of gait speed, Timed Up-and-Go, grip strength, BMI, orthostatic hypotension, 
and osteoporosis (appendix table 5).  
 
Dispensed anti-cholinergic medications and falls 
Pharmacy dispensing records were available for 1,553 (58%) participants. Of 
these, 116 (7%) were dispensed medications with definite anti-cholinergic activity in 
the 30 days before baseline interview, whilst 707 (46%) were dispensed only 
medications with possible anti-cholinergic activity (table 4). For men, baseline use of 
medications with definite anti-cholinergic activity was again not significantly associated 
with fallers or number of falls after covariate adjustment, but was significantly 
associated with subsequent injurious falls (aRR 2.53, 95% CI 1.15 to 5.54). No 
associations were observed for women. 
 
DISCUSSION 
 
In this prospective study of community-dwelling Irish adults aged 65 years and 
older, the use of medications with anti-cholinergic activity was associated with a greater 
risk of subsequent injurious falls in men. However, no association was seen for having 
suffered any falls (including non-injurious) or the total number of falls, and no 
association was seen among women.  The findings were robust to adjustment for 
objective health measures and when using pharmacy dispensing records.  
The main strength of our study was the use of a large randomly sampled 
population-representative cohort with detailed pharmacy records. Longitudinal follow-
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up ensured medication exposure preceded the falls outcomes. Participants underwent a 
detailed assessment of their socioeconomic characteristics, cognitive and physical 
health, allowing us to examine potential confounders usually unavailable to 
pharmacoepidemiological studies.  We limited confounding by indication by adjusting 
for many indications for anti-cholinergic medications. We fully adjusted for baseline 
disability and multimorbidity, modelling all health conditions simultaneously, instead of 
using a comorbidity index which provides only limited confounding control 37. Most 
health variables were self-reported, but objective measures added little additional 
confounding control beyond the self-report measures.  Those not completing the health 
assessment (41%) were more likely to have public healthcare coverage, less education, 
be single and smoke. However, associations were similar when restricting our primary 
analysis to only those who underwent a health assessment.  The possibility of residual 
confounding cannot be excluded. However, with extensive adjustment for health-related 
risk factors, the comprehensive nature of the TILDA health assessment, and as 
adjustment for objective health measures did not reduce the main associations, we feel 
that significant residual confounding is unlikely.  
To better ascertain medications adhered to, participants were asked for 
medications taken regularly, and trained interviewers viewed medication packages. We 
cannot be sure whether participants adhered to their medications, however, adherence 
decreases with increasing regimen complexity and therefore the impact of a large anti-
cholinergic burden on falls incidence would potentially be under-estimated 38.   
Although self-reported medication use might be subject to recall bias, we found 
little evidence for this when comparing self-report to dispensing records 29. We did, 
however, find that some regularly dispensed medications with definite anti-cholinergic 
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activity (in particular psycholeptics) were under-reported 29. To compare results using 
different medication data sources, we repeated analyses using pharmacy dispensing 
records, although these may less accurately reflect adherence.  Participants with 
dispensing records were covered by public healthcare, hence were older, less educated, 
had less income and employment than others. They also reported more chronic 
diseases, medications, and depressive symptoms.  However, conclusions were similar 
when restricting our primary analysis to only those with linked pharmacy records. We 
do not know precisely when the injurious falls occurred and therefore what medications 
were being taken at that time.  However, the use of definite anti-cholinergics seems 
reasonably stable; of those reporting use at baseline, 57% were also dispensed them 
one year before, and 66% were still reporting regular use at the second interview, with 
associations consistent in the subgroup maintaining use (results not shown).  Although 
the reported use of definite anti-cholinergics in this dementia-free community-dwelling 
population was low, usage was greater in the pharmacy records, and is significantly 
greater in other settings 11,20,23.   Also, very few definite anti-cholinergics had an ACB 
score of 2, and when excluded from analysis, the association between definite anti-
cholinergics use and injurious falls in men remained unaffected. 
The ACB has not been validated against in vitro measures of anti-cholinergic 
activity, although it is uncertain whether assays reflect anti-cholinergic activity in the 
brain, and not all relevant drugs have been assayed in vitro 39,40. The ACB scale was 
chosen for this analysis as it is increasingly widely used 17,19, has convergent validity as 
a measure of anti-cholinergic activity as it has been repeatedly demonstrated to 
correlate with cognitive impairment 17,19, and is recently updated with respect to 
mediations in use in Ireland during the study period30. The scale is limited by the 
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evidence base available on the anti-cholinergic properties of many medications, 
particularly regarding effects on the Central Nervous System (CNS). Work is underway 
to understand the potential anti-cholinergic activity exerted in the CNS by varying doses 
and varying medications to enable future refinement of the ACB scale. Comparing 
results using different anti-cholinergic scales is an aim for future research.  
Fewer than 2% of participants were excluded due to missing falls or medication 
data. Missing data indicators were used for income, alcoholism, depressive symptoms 
and cognition in the main analysis, but use of multiple imputation did not alter our 
findings (results not shown). Fifteen percent of participants dropped out between the 
interviews; they were more likely to be smokers, have less education and lower 
cognition. Use of inverse probability attrition weights lead to very similar findings, thus 
our results are unlikely to be affected by differential drop-out. 
Falling outcomes may be misclassified. Falls under-reporting is found more 
commonly than over-reporting in the elderly, however as more significant events, 
injurious falls are more accurately recalled 41. We have no reason to believe that recall 
would be differential and the effect of falls under reporting was minimized by excluding 
institutionalized participants and those with dementia. Although our falling rate was 
slightly lower than in other community-dwelling populations, this could be because our 
cohort excludes those with poor cognition 8,42. The recall of falls was also over a longer 
period than optimal 41. Restricting analysis to participants with less than two years 
between interviews and other attempts to select participants with better quality 
reporting strengthened our associations, but reduced the applicability of our results and 
so were not reported.  
18 
 
18 
 
Previous studies have linked multiple medication use (polypharmacy) to falling, 
although more recent work has shown that the type of medications concurrently taken 
is more important for falls risk than simply their number 43,44. Although lacking 
statistical power, analyses suggested that the anti-cholinergic scale was more strongly 
associated with injurious falls than polypharmacy (results not shown). Few studies have 
examined the relationship between anti-cholinergic medication use and falling 11,20,21,23, 
and to the best of our knowledge, none have examined injurious falls. The Canadian 
Multicentre Osteoporosis Study found no association between strongly anti-cholinergic 
medication use and incident fallers or fractures over 10 years follow-up in adults aged 
over 50 years, although medication was assessed at baseline and 5-year follow-up only, 
and sex-specific associations were not reported 23. A Finnish population-based study 
also reported no associations between baseline anti-cholinergic use and fractures 3 and 
6 years later either in men or women, but the study was potentially under-powered by 
recording only 29 male fractures24. No association between baseline use of medication 
with anti-cholinergic activity and subsequent fallers was reported among community-
dwelling older adults in France 21.  While a positive association for regular anti-
cholinergic medication use was reported, this definition included use post-falling.  
Contrary to our findings, two studies reported more anti-cholinergic medication use 
among subsequent fallers, albeit in higher risk populations of psychiatric inpatients and 
residential care facility residents 11,20. Also, in one case these findings were presented in 
combination with sedatives 20 and in the other only as crude associations 11.  
Prospective studies also support a positive effect of anti-cholinergic medication 
use on functional and cognitive decline 19,22. Cognitive decline is unlikely to mediate our 
findings as adjustment for cognitive measures at the second interview had no 
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substantial effect (results not shown). Although we adjusted for the animal naming test 
in the primary analysis, additional adjustment for the MMSE or MoCA (available for 
fewer participants), had no effect on our findings (results not shown). The association 
between injurious falls and anti-cholinergic burden contributes to the reported link 
between ACB and mortality 17.  
Intervention studies are needed to test whether reducing anti-cholinergic 
burden can prevent injurious falls. One randomised controlled trial among 93 adults 
aged 65 and older found that gradual withdrawal of psychotropic medications was 
effective at reducing the number of falls and injurious falls, but not any fall 45. 
Educational visits to doctors and pharmacists were effective at reducing the prescribing 
of highly anti-cholinergic antidepressants to elderly community-dwelling patients 46, 
and subsequently were successful at reducing anti-cholinergic side-effects over the next 
year 47. 
Few studies have examined gender-specific anti-cholinergic adverse effects. Two 
Finnish studies have shown a greater effect of anticholinergic medications with fracture 
and mortality post fracture among men but not women 24,48. They suggested 
interactions with cardiovascular disease and smoking 48, or that alcohol use and 
untreated osteoporosis are underlying factors 24, however our reported associations are 
not affected by adjustment for alcohol use or bone density. The differing nature of 
injurious falls typically suffered by men and women 5 could explain our reported sex 
difference, however we did not record these details and so cannot test this hypothesis. 
Injurious falls are serious and costly, therefore medication risks need to be fully 
evaluated in vulnerable patients 1,49.  Future studies are needed to examine whether 
injurious falls risks vary by the anti-cholinergic activity in the CNS and therapeutic class 
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of medications used, and to confirm the sex difference. Prescribing decisions would be 
improved with further understanding of the injuries experienced when taking anti-
cholinergic medications and of the underlying mechanisms.  
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GRAPHICS 
 
Tables  
 
Table 1. Baseline characteristics of men and women reporting an injurious fall by the second interview (N=2,696) 
 
Men 
 
Women 
 
No injurious fall 
(n=1,175) 
Injurious fall 
(n=111)   
No injurious fall 
(n=1,177) 
Injurious fall 
(n=233)  
Baseline characteristics  n % n % pa   n % n % pa 
Sociodemographics 
           Age, mean (SD) 72.4 5.9 73.3 6.1 0.13 
 
72.6 5.9 74.0 6.7 0.006 
Third/higher education 359 30.6 33 29.7 0.86 
 
297 25.2 55 23.6 0.55 
Retired 966 82.2 101 91.0 0.02 
 
670 56.9 132 56.7 0.94 
Household income < €20,000b 346 29.5 48 43.2 0.003 
 
474 40.3 103 44.2 0.23 
Lives alone 268 22.8 35 31.5 0.04 
 
421 35.8 104 44.6 0.01 
Current smoker 149 12.7 11 9.9 0.40 
 
139 11.8 30 12.9 0.65 
Alcoholismb 115 11.2 9 9.2 0.55 
 
38 3.2 9 3.9 0.84 
Health 
           Number of health conditions 
    
0.002 
 
    
0.007 
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29 
 
0 168 14.3 13 11.7 
  
101 8.6 13 5.6 
 1 268 22.8 12 10.8 
  
227 19.3 39 16.7 
 2 273 23.2 26 23.4 
  
266 22.6 46 19.7 
 3 200 17.0 21 18.9 
  
219 18.6 39 16.7 
 4 139 11.8 14 12.6 
  
182 15.5 36 15.5 
 5+ 127 10.8 25 22.5 
  
182 15.5 60 25.8 
 Moderate/severe chronic pain 215 18.3 28 25.7 0.001 
 
364 30.9 97 41.6 0.002 
Urinary incontinence 109 9.3 16 14.4 0.17 
 
230 19.5 54 23.1 0.09 
Trouble falling asleep 274 23.3 39 35.1 0.01 
 
537 45.6 126 54.0 0.03 
Depressive symptoms, median (IQR) b 3 0-6 4 1-8 <.001 
 
4 1-8 6 2-11 <.001 
Disability (ADL or IADL) 152 12.9 23 20.7 0.01 
 
177 15.1 62 26.6 <.001 
Fair/poor self-rated vision 96 8.2 17 15.3 0.01 
 
130 11.0 35 15.0 0.08 
Fair/poor self-rated hearing 257 21.9 31 27.9 0.14 
 
188 16.0 51 21.9 0.03 
Cognition, animal naming mean (SD)b 19.6 6.5 18.6 6.2 0.12 
 
18.8 6.6 18.3 6.9 0.37 
Healthcare utilisation 
           Public healthcare coverage 803 68.4 81 73.0 0.32 
 
873 74.2 187 80.3 0.05 
Hospital admission in past year 181 15.4 28 25.2 0.007 
 
158 13.4 52 22.3 <.001 
Fall-related history  
    
  
    
 Fall in the last year 209 17.8 46 41.4 <.001 
 
238 20.2 94 40.3 <.001 
History of hip or wrist fracture 153 13.0 17 15.3 0.50 
 
185 15.7 60 25.8 <.001 
History of fainting/blackouts 180 15.3 25 22.5 0.05   217 18.4 53 22.7 0.13 
a Chi-square test for binary and ordinal variables, t-test for continuous variables, Mann-Whitney U-test for depressive symptoms. 
30 
 
30 
 
b Missing data (number of participants): Income (233), Alcoholism (339), Depressive symptoms (49), Cognition (10) 
Abbreviations: SD, standard deviation; IQR, Interquartile range; ADL, Activities of Daily Living; IADL, Instrumental Activities of Daily Living.  
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Table 2. Multivariable associations (and 95% CI) between the use of medications and incident falls by the most severely anti-cholinergic medication 
used (N=2,696) 
Max   Faller    Number of falls   Injurious fall 
ACB N n (%)  RR (95% CI)a   
Rate per 
1000PY 
IRR (95% CI)a   n (%)  RR (95% CI)a 
MEN 
         None 777 160 (20.6) 1.00 
 
181 1.00 
 
53 (6.8) 1.00 
Possible 459 105 (22.9) 0.93 (0.73 to 1.18) 
 
227 0.98 (0.71 to 1.37) 
 
46 (10.0) 1.29 (0.82 to 2.01) 
Definite 50 22 (44.0) 1.16 (0.75 to 1.81) 
 
520 1.74 (0.90 to 3.38) 
 
12 (24.0) 2.55 (1.33 to 4.88) 
WOMEN 
         None 800 222 (27.7) 1.00 
 
212 1.00 
 
126 (15.7) 1.00 
Possible 542 177 (32.7) 0.97 (0.81 to 1.16) 
 
276 1.01 (0.81 to 1.26) 
 
91 (16.8) 0.79 (0.61 to 1.04) 
Definite 68 25 (36.8) 0.94 (0.67 to 1.33)  407 1.02 (0.67 to 1.57)  16 (23.5) 0.97 (0.57 to 1.6) 
 
a Adjusted for baseline covariates: age, living alone, education, employment status, income, smoking status (never, past, current), alcoholism (CAGE 
score of ≥2), time between interviews, each comorbidity (listed in methods section), incontinence, pain, sleep problems, depressive symptoms 
(quintiles), cognition (quintiles), self-rated vision, self-rated hearing, disability (none, iADL, ADL), public healthcare coverage, history of falls, 
fracture, fainting, and hospitalisation, and number of non anti-cholinergic antihypertensives, diuretics, antipsychotics, sedatives and hypnotics, 
antidepressants, and other medications.  
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Abbreviations: RR, relative risk; IRR, Incidence rate ratio; CI, confidence interval; PY, person-year; ACB, Anti-cholinergic Cognitive Burden.  
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Table 3. Multivariable associations (and 95% CI) between the use of medications and incident falls by Anti-cholinergic Cognitive Burden score 
(N=2,696) 
 
ACB   Faller    Number of falls   Injurious fall 
sum N n (%)  RR (95% CI)a   Rate per 1000PY IRR (95% CI)a   n (%)  RR (95% CI)a 
MEN 
         0 777 160 (20.6) 1.00 
 
181 1.00 
 
53 (6.8) 1.00 
1 303 63 (20.8) 0.93 (0.71 to 1.22) 
 
205 0.99  (0.70 to 1.42) 
 
29 (9.6) 1.44  (0.89 to 2.33) 
2 123 34 (27.6) 1.02 (0.72 to 1.45) 
 
295 1.20  (0.74 to 1.94) 
 
12 (9.8) 1.33  (0.68 to 2.60) 
3 41 10 (24.4) 0.70 (0.39 to 1.27) 
 
176 0.66  (0.29 to 1.48) 
 
4 (9.8) 0.74  (0.25 to 2.21) 
4 20 6 (30.0) 0.96 (0.44 to 2.11) 
 
318 1.30  (0.48 to 3.55) 
 
4 (20.0) 2.19  (0.71 to 6.75) 
5+ 22 14 (63.6) 1.71 (1.03 to 2.84) 
 
839 2.78  (1.08 to 7.11) 
 
9 (40.9) 4.95 (2.11 to 11.65) 
WOMEN 
         0 800 222 (27.7) 1.00 
 
212 1.00 
 
126 (15.7) 1.00 
1 360 112 (31.1) 0.96 (0.79 to 1.18) 
 
248 1.00  (0.78 to 1.28) 
 
54 (15.0) 0.77  (0.56 to 1.05) 
2 125 43 (34.4) 0.99 (0.75 to 1.32) 
 
308 1.02  (0.72 to 1.45) 
 
24 (19.2) 0.89  (0.60 to 1.33) 
3 69 22 (31.9) 0.91 (0.63 to 1.31) 
 
299 0.97  (0.63 to 1.49) 
 
12 (17.4) 0.75  (0.41 to 1.37) 
4 30 13 (43.3) 1.06 (0.68 to 1.66) 
 
510 1.32  (0.73 to 2.38) 
 
8 (26.7) 1.02  (0.54 to 1.93) 
34 
 
34 
 
5+ 26 12 (46.2) 0.89 (0.55 to 1.45)   510 0.79  (0.41 to 1.53)   9 (34.6) 1.03  (0.53 to 2.03) 
a Adjusted for baseline covariates: age, living alone, education, employment status, income, smoking status (never, past, current), alcoholism (CAGE 
score of ≥2), time between interviews, each comorbidity (listed in methods section ), incontinence, pain, sleep problems, depressive symptoms 
(quintiles), cognition (quintiles), self-rated vision, self-rated hearing, disability (none, iADL, ADL), public healthcare coverage, history of falls, 
fracture, fainting, and hospitalisation, and number of other non anti-cholinergic antihypertensives, diuretics, antipsychotics, sedatives and hypnotics, 
antidepressants, and other medications.  
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Table 4. Multivariablea associations (95% CI) between the baseline use of medications and incident falls for men and women with pharmacy record 
linkage by the most severely anti-cholinergic medication dispensed (N=1,553) 
 
Max   Faller    Number of falls   Injurious fall 
ACB N n (%)  RR (95% CI)a   
Rate per 
1000PY 
IRR (95% CI)a   n (%)  RR (95% CI)a 
MEN 
         None 345 77 (22.3) 1.00 
 
184 1.00 
 
29 (8.4) 1.00 
Possible 314 77 (24.5) 0.98 (0.72 to 1.32) 
 
241 1.14 (0.76 to 1.71) 
 
33 (10.5) 1.24 (0.67 to 2.29) 
Definite 44 14 (31.8) 1.13 (0.65 to 1.97) 
 
331 1.67 (0.84 to 3.32) 
 
9 (20.5) 2.53 (1.15 to 5.54) 
WOMEN 
         None 385 97 (25.2) 1.00 
 
187 1.00 
 
55 (14.3) 1.00 
Possible 393 131 (33.3) 1.07 (0.84 to 1.37) 
 
299 1.15 (0.86 to 1.55) 
 
78 (19.9) 1.05 (0.74 to 1.49) 
Definite 72 29 (40.3) 1.13 (0.78 to 1.64)  430 1.28 (0.80 to 2.04)  19 (26.4) 1.25 (0.77 to 2.02) 
 
 
a Adjusted for baseline covariates: age, living alone, education, employment status, income, smoking status (never, past, current), alcoholism (CAGE 
score of ≥2), time between interviews, each comorbidity (listed in methods section), incontinence, pain, sleep problems, depressive symptoms 
(quintiles), cognition (quintiles), self-rated vision, self-rated hearing, disability (none, iADL, ADL), history of falls, fracture, fainting, and 
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hospitalisation, and number of other non anti-cholinergic antihypertensives, diuretics, antipsychotics, sedatives and hypnotics, antidepressants, and 
other medications dispensed in the previous 30 days. 
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FIGURES 
 
Figure 1. Selection of participants with longitudinal falls data for analysis 
 
 
 
a For the 503 dropping out by the second interview, the main reasons were refusal 
(76%), non-contact (6%), and moving abroad (2%). 
Participants at 
baseline in TILDA aged 
≥65 years (n=3,507) 
Followed up  
(n=3,441) 
Completed follow - 
up (n=2,785) 
By wave 2:  
- Died (n=153) 
- Drop outa (n=503) 
Analysed (n=2,696) 
Excluded: 
- Dementia (n=13) 
- No medication data (n=53) 
Excluded: 
- Dementia (n=30) 
- Institutionalised (n=16) 
- No falls data (n=5) 
- Proxy fall report (n=38)  
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Appendix tables  
 
Appendix table 1: Medications with anti-cholinergic activity recorded at baseline in TILDA 
by Anti-cholinergic Cognitive Burden score (N=2,696)  
 
Drug class Drug name 
Definite anti-cholinergics (ACB score 3) 
Antispasmodics Butylscopolamine 
Urologicals Fesoterodine 
  Flavoxate 
  Oxybutynin 
  Solifenacin 
  Tolterodine 
  Trospium 
Anti-cholinergics used for Parkinson’s disease and drug-induced movement 
disorder Biperiden 
  Procyclidine 
Antipsychotics Chlorpromazine 
  Olanzapine 
  Quetiapine 
  Trifluoperazine 
Antidepressants Amitriptyline 
  Clomipramine 
  Paroxetine 
  Trimipramine 
Antihistamines Chlorphenamine 
  Diphenhydramine 
  Promethazine 
 
Hydroxyzine 
Definite anti-cholinergics (ACB score 2) 
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Cardiovascular Captopril and hydrochlorothiazide 
Analgesics Nefopam 
Antiepileptics Carbamazepine 
Antiparkinsonians Amantadine 
Antipsychotics Zuclopenthixol 
  Pimozide 
Possible anti-cholinergics (ACB score 1) 
H2 antagonists Cimetidine 
 
Famotidine 
 
Ranitidine 
Antispasmodics Alverine 
 
Mebeverine 
 
Fybogel mebeverine  
Antidiarrheals Diphenoxylate 
 
Loperamide 
Antithrombotics Warfarin 
Cardiovascular Aldactide 
 
Atenolol 
 
Bendroflumethiazide 
 
Captopril 
 
Clonidine 
 
Digoxin 
 Dipyridamole 
 
Disopyramide 
 
Doxazosin 
 
Furosemide 
 
Hydrochlorothiazide  
 
Indoramin 
 
Isosorbide Dinitrate 
 
Isosorbide Mononitrate 
 
Methyldopa 
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Metolazone 
 
Metoprolol 
 
Nifedipine 
 
Propafenone 
 
Quinidine 
 
Torasemide 
Corticosteroids Hydrocortisone 
 
Triamcinolone Nasal Preparation 
Musculoskeletal drugs Baclofen 
 
Colchicine 
Analgesics Buprenorphine 
 
Codeine 
 
Dextropropoxyphene 
 
Dihydrocodeine 
 
Fentanyl 
 
Hydromorphone 
 
Meptazinol 
 
Morphine 
 
Oxycodone 
 
Tramadol 
Antipsychotics Amisulpride 
 
Aripiprazole 
 
Flupentixol 
 
Fluphenazine 
 
Haloperidol 
 
Prochlorperazine 
 
Risperidone 
 
Sulpiride 
Benzodiazepines Alprazolam 
 
Diazepam 
Antidepressants Citalopram 
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Escitalopram 
 
Mirtazapine 
 
Tranylcypromine 
 
Trazodone 
 
Venlafaxine 
Antihistamines Cetirizine 
 Cinnarizine 
 Desloratadine 
 Flunarizine 
 
Levocetirizine 
 Loratadine 
Drugs for obstructive airway diseases Aminophylline 
 
Fenoterol  
 
Ipratropium bromide 
 
Salbutamol 
 
Theophylline 
 
Tiotropium bromide 
  
 
42 
 
42 
 
Appendix Table 2. Baseline health assessment measures of men and women by subsequent injurious fall (N=1,588)   
 
Men 
 
Women 
 
No injurious fall 
(n=700) 
Injurious fall (n=61) 
  
No injurious fall 
(n=697) 
Injurious fall (n=130) 
 Health assessment measurea N % n % pb  N % n % pb 
Grip strength (kg), mean (SD) 30.6 6.9 29.1 6.9 0.11 
 
17.7 4.7 16.8 4.1 0.03 
Timed Up-and-Go (s), mean (SD) 9.4 2.1 9.7 2.0 0.18 
 
9.6 2.6 9.8 2.2 0.19 
Gait speed (cm/s), mean (SD) 129.8 19.1 125.1 18.3 0.06 
 
125.2 20.9 120.2 20.8 0.01 
BMI (kg/m2), mean (SD) 29.2 4.4 29.1 4.4 0.91 
 
28.1 4.9 27.6 4.8 0.32 
Orthostatic hypotension 
           Normal 602 86.0 50 82.0 0.71 
 
564 80.9 93 71.5 0.08 
No recovery after 40s 53 7.6 7 11.5 
  
62 8.9 15 11.5 
 No recovery after 110s 29 4.1 3 4.9 
  
47 6.7 16 12.3 
 Osteoporosis (heel ultrasound) 
           Normal (SI>86%) 438 62.6 44 72.1 0.23 
 
184 26.4 28 21.5 0.71 
Osteopenia (65%<SI≤86%) 223 31.9 12 19.7 
  
352 50.5 70 53.8 
 Osteoporosis (SI≤65%) 33 4.7 4 6.6     155 22.2 31 23.8   
a Missing data (number of participants): Grip strength (9), Timed Up-and-Go (16), Gait speed (38), BMI (7), Orthostatic hypotension (47), 
Osteoporosis (14) 
b Chi-square test for binary and ordinal variables, t-test for continuous variables. 
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Abbreviations: SI, Index of bone stiffness. 
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Appendix Table 3. Multivariablea associations (and 95% CI) between the use of medications and incident falls by the most severely anti-cholinergic 
medication used, inverse-probability of attrition weighted (N=2,696)   
 
Max   Faller Falling rate Injurious fall 
ACB  N Adjusted RRa Adjusted IRRa Adjusted RRa 
MEN 
    None 777 1.00 1.00 1.00 
Possible 459 0.93 (0.73 to 1.18) 0.98 (0.71 to 1.34) 1.30 (0.83 to 2.03) 
Definite 50 1.16 (0.75 to 1.81) 1.71 (0.91 to 3.22) 2.50 (1.33 to 4.71) 
WOMEN 
    None 800 1.00 1.00 1.00 
Possible 542 0.97 (0.81 to 1.17) 1.01 (0.81 to 1.24) 0.79 (0.60 to 1.03) 
Definite 68 0.92 (0.65 to 1.30) 0.99 (0.63 to 1.56) 0.93 (0.55 to 1.57) 
 
a Adjusted for baseline covariates: age, living alone, education, employment status, income, smoking status (never, past, current), alcoholism (CAGE 
score of ≥2), time between interviews, each comorbidity (listed in methods section), incontinence, pain, sleep problems, depressive symptoms 
(quintiles), cognition (quintiles), self-rated vision, self-rated hearing, disability (none, iADL, ADL), public healthcare coverage, history of falls, 
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fracture, fainting, and hospitalisation, number of possibly anti-cholinergic medications, and number of other non anti-cholinergic antihypertensives, 
diuretics, antipsychotics, sedatives and hypnotics, antidepressants, and other medications. 
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Appendix Table 4. Multivariable relative risks (and 95% CI) between the use of medications with definite anti-cholinergic activity and incident 
injurious falls, by age and sex (N=2,696)  
Sex and age group N 
Definite 
anticholinergic 
(%) 
Injurious 
fall (%)  RR (95% CI)a 
MEN 
    Aged 65-69 years 491 15 (3.1) 4 (26.7) 3.71 (1.05 to 13.13) 
Aged 70-74 years 374 17 (4.5) 5 (29.4) 3.37 (1.08 to 10.56) 
Aged 75+ years 421 18 (4.3) 3 (16.7) 1.50 (0.52 to 4.34) 
WOMEN 
    Aged 65-69 years 502 19 (3.8) 5 (26.3) 0.88 (0.32 to 2.44) 
Aged 70-74 years 403 22 (5.5) 6 (27.3) 1.98 (0.84 to 4.63) 
Aged 75+ years 505 27 (5.3) 5 (18.5) 0.58 (0.25 to 1.35) 
 
a Adjusted for baseline covariates: age, living alone, education, employment status, income, smoking status (never, past, current), alcoholism (CAGE 
score of ≥2), time between interviews, each comorbidity (listed in methods section), incontinence, pain, sleep problems, depressive symptoms 
(quintiles), cognition (quintiles), self-rated vision, self-rated hearing, disability (none, iADL, ADL), public healthcare coverage, history of falls, 
fracture, fainting, and hospitalisation, possibly anti-cholinergic medications, and number of other non anti-cholinergic antihypertensives, diuretics, 
antipsychotics, sedatives and hypnotics, antidepressants, and other medications.  
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Appendix Table 5. Multivariable associations (and 95% CI) between the use of medications and incident falls for men and women completing a 
health assessment by the most severely anti-cholinergic medication used (N=1,588) 
Max   Faller   Number of falls   Injurious fall 
ACB N 
Adjusteda (95% 
CI) 
Fully adjusteda (95% 
CI) 
  
Adjusteda (95% 
CI) 
Fully adjusteda (95% 
CI) 
  Adjusteda (95% CI) 
Fully adjusteda (95% 
CI) 
MEN 
         None 489 1.00 1.00 
 
1.00 1.00 
 
1.00 1.00 
Possible 247 0.65 (0.46 to 0.90) 0.62 (0.45 to 0.87) 
 
0.75 (0.48 to 1.18) 0.66 (0.42 to 1.04) 
 
0.76 (0.42 to 1.37) 0.70 (0.35 to 1.39) 
Definite 25 1.00 (0.52 to 1.92) 0.88 (0.42 to 1.84) 
 
1.70 (0.68 to 4.24) 1.38 (0.55 to 3.46) 
 
2.27 (0.78 to 6.64) 2.27 (0.71 to 7.27) 
WOMEN 
         None 510 1.00 1.00 
 
1.00 1.00 
 
1.00 1.00 
Possible 284 0.98 (0.77 to 1.24) 0.96 (0.75 to 1.23) 
 
0.97 (0.73 to 1.30) 0.93 (0.70 to 1.24) 
 
0.9 (0.63 to 1.30) 0.83 (0.56 to 1.22) 
Definite 33 1.02 (0.58 to 1.79) 0.90 (0.50 to 1.61)   1.44 (0.81 to 2.55) 1.21 (0.68 to 2.13)   1.36 (0.57 to 3.25) 1.16 (0.43 to 3.11) 
 
a Adjusted for baseline covariates: age, living alone, education, employment status, income, smoking status (never, past, current), alcoholism (CAGE 
score of ≥2), time between interviews, each comorbidity (listed in methods section), incontinence, pain, sleep problems, depressive symptoms 
(quintiles), cognition (quintiles), self-rated vision, self-rated hearing, disability (none, iADL, ADL), public healthcare coverage, history of falls, 
fracture, fainting, and hospitalisation, and number of other non anti-cholinergic antihypertensives, diuretics, antipsychotics, sedatives and hypnotics, 
antidepressants, and other medications.  
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b Also adjusted for gait speed (quintiles), Timed Up-and-Go (quintiles), grip strength (quintiles), BMI (quintiles), orthostatic hypotension (normal, 
no recovery after 40s, no recovery after 110s), osteoporosis heel ultrasound (normal, osteopenia, osteoporosis). 
  
 
